

# Supporting Information

Cai et al. 10.1073/pnas.1111233109

## SI Materials and Methods

**Cells and Constructs.** Jurkat-KCa3.1 T cells were generated as previously described (1) and cultured in RPMI + 10% FBS. GFP-tagged class II PI3K C2 $\alpha$  (PI3KC2 $\alpha$ ) and PI3KC2 $\beta$  were kindly provided by J. Domin, Imperial College, London, United Kingdom. The PI3KC2 $\beta$  kinase dead mutant was generated by substituting lysine 850 to arginine and tripartite motif containing protein 27 (TRIM27) Really Interesting New Gene (RING) mutant was generated by substituting C3/H1/C4/C5 in the cysteine-rich zinc binding domain to S3/Q1/S4/S5 (2).

All T-cell transfection were performed using AMAXA reagents according to the manufacturer's protocols (Amata Biosystems). Human CD4 T cells were isolated from peripheral adult blood buffy coats (New York Blood Center) using the CD4 isolation kit from Miltenyi Biotec according to manufacturer's protocol. We routinely obtained >95% CD4 T cells as assessed by FACS.

**Antibodies.** Anti-TRIM27 antibodies were purchased from IBL America and anti-PI3KC2 $\beta$  were purchased from BD Transduction Laboratories. Anti-PI3KC2 $\beta$  antibody M02 (clone 3E5) (Novus Biologicals) was used to both immunoblot and immunoprecipitate mouse PI3KC2 $\beta$ .

**In Vivo Ubiquitination Assay.** GFP-tagged PI3KC2 $\alpha$  and PI3KC2 $\beta$  were expressed with or without FLAG-TRIM27 together with His<sub>6</sub>-ubiquitin in HEK 293 cells. Transfected cells were then lysed in 6 M guanidinium and ubiquitinated proteins were purified using Nickel (Ni)-NTA beads followed by Western blotting with anti-GFP or anti-FLAG antibodies, as previously described (3).

To assess whether TRIM27 stimulates K48, K63, poly-, or monoubiquitination of PI3KC2 $\beta$ , HEK 293 cells were transfected with GFP-PI3KC2 $\beta$  and FLAG-TRIM27. Twenty-four hours later, cells were lysed in 1% SDS lysis buffer and, after diluting to 0.1% SDS, PI3KC2 $\beta$  was immunoprecipitated with anti-GFP antibodies and then Western blotted with the Lys48-specific antibody (Millipore; clone Apu2), the polyubiquitin-specific antibody (Millipore; clone FK1), of the Lys63-specific antibody (Millipore; clone Apu3), as previously described (4, 5).

**Whole-Cell Patch Clamp. CD4 T cells.** Whole-cell patch clamping was performed on activated CD4 T cells 48 h after stimulation with anti-CD3 and antiCD28 antibodies, as previously described (6), with some modification (7).

**Jurkat-KCa3.1 T cells.** Whole-cell patch clamping on Jurkat-KCa3.1 T cells was performed as previously described (1).

To verify that TRIM27 modulated KCa3.1 channel activity via PI3KC2 $\beta$ , which resulted in changes in levels PI3P, PI3P (100 nM) was added into the pipette solution during patch clamping in Jurkat-KCa3.1 cells overexpressing GFP-TRIM27 (8). PI(3)P diC16 [C<sub>41</sub>H<sub>45</sub>N<sub>3</sub>O<sub>16</sub>P<sub>2</sub> (C<sub>6</sub>)] as well as other PIs were purchased from Echelon Biosciences and used according to specifications at a concentration of 100 nM in the pipette solution.

**siRNA Transfections and Lentiviral Infection with GFP-TRIM27(WT) or TRIM27(RING MT).** For siRNA transfection, unstimulated human CD4 T cells or Jurkat-KCa3.1 cells were electroporated using AMAXA reagents (Amata Biosystems) according to the manufacturer's protocol. For human CD4 T cells, cells were rested overnight after transfection, and subjected to whole-cell patch clamp following stimulation for 2 d with anti-CD3 and anti-CD28 antibodies. Jurkat-KCa3.1 underwent whole-cell patch clamp 48 h after transfection (1). The following TRIM27 siRNAs (Qiagen)

were used: siRNA 1, sense strand: 5'-GAGUACUCGGGAG-GGAAATT-3'; antisense strand: 5'-UUUCCCUCCGAGUACUCAG-3'; siRNA 2, sense strand: 5'-CACCUCUGUUAUG-AGAUAATT-3'; antisense strand: 5'-UUAUCUAUAACAG-AGGUGGG-3'.

For rescue of siRNA-transfected cells, T cells were infected with a vesicular stomatitis virus-G pseudotyped HIV derived lentivirus expressing either FLAG-TRIM27(WT) or FLAG-TRIM27(RING MT) together with internal ribosome entry site-GFP, as previously described (7, 9). GFP positive cells were then subjected to whole cell patch clamp.

**Immunoprecipitation and Western Blots.** Immunoprecipitation and Western blots were performed as previously described (8, 10).

**Intracellular Ca<sup>2+</sup> Activity.** Cells were loaded at 1 × 10<sup>6</sup> cells/mL with 5  $\mu$ M Fura-2:00 AM ester (Molecular Probes) in RPMI medium for 30 min at room temperature, washed, and then resuspended in RPMI. Cells were attached to poly(L)lysine-coated coverslips for 20 min in a RC-20 bath flow chamber (Warner Instrument) and fura-2 fluorescence was recorded (Delta Ram; PTI Inc.) at excitation wavelengths of 340 and 380 nm. Background fluorescence was obtained by treating the cells with 100 mM MnCl<sub>2</sub> in the end of the experiment. Data are represented as the ratio 340/380 after background subtraction. Cells were perfused with the bath solution (composition described before) in the presence or absence of extracellular Ca<sup>2+</sup> and stimulated with 5  $\mu$ g/mL of anti-CD3 cross linked with 5  $\mu$ g/mL of rat anti-mouse IgG.

**PI3K Assay.** HEK 293 cells were transfected with GFP-PI3KC2 $\beta$  WT or kinase dead mutant alone or together with TRIM27 (WT) or TRIM27 (RING MT). Cells were lysed in the presence of protease inhibitors, phosphatase inhibitors, and 5  $\mu$ M ubiquitin-aldehyde (Boston Biochem), and PI3K assay was performed on anti-GFP immunoprecipitates, as previously described (1). Lymphocytes from *TRIM27*<sup>-/-</sup> and *TRIM27*<sup>+/+</sup> mice were lysed as above and PI3K assay was performed on anti-PI3KC2 $\beta$  (Novus Biologicals) immunoprecipitates, also as previously described (1).

**Generation of *TRIM27*<sup>-/-</sup> Mice.** ES cell line (clone ID 345D11, strain 129/ola) that contained an exon-trapping plasmid pUPA integrated between exon 1 and exon 2 of the *TRIM27* gene was purchased from The Center for Modeling Human Disease at the University of Toronto. (<http://www.cmhd.ca/genetrap/index.html>). ES cells (strain 129/ola) were injected into C57BL/6 blastocyst by the transgenic facility at the New York University Langone Medical Center (New York) and chimeric mice were obtained. *TRIM27*<sup>+/-</sup> mice were backcrossed five generations with C57BL/6 and then used to generate *TRIM27*<sup>-/-</sup> C57BL/6 mice in these studies.


Primers used to genotype mice: TRIM27 F WT (mouse chromosome 13 genomic contig, GenBank Accession Number NT\_039578.7, 10099908–10099931) CATTAGCCACTCTCAGACTCGGG; TRIM27 R (mouse chromosome 13 genomic contig, GenBank Accession Number NT\_039578.7, 10100140–10100166). AGC-GAGTGAAATGATACAGGTGACAGC; pUPA F KO GAT-AAGTTGCTGGCCAGCTTACCTCCC. The WT PCR product (primers TRIM27 F WT and TRIM27 R) is 259 bp and the knockout PCR product (primers pUPA F KO and TRIM27 R) is 600 bp.

**Purification and Differentiation *TRIM27*<sup>-/-</sup> and *TRIM27*<sup>+/+</sup> CD4 Th Subsets.** CD4<sup>+</sup> T cells were purified on MACS beads (Miltenyi Biotec) from WT or *TRIM27*<sup>-/-</sup> spleens as previously described (11). Various CD4 T-cell subsets were generated by


culturing CD4 cells purified from spleen cells under Th1 polarizing conditions (100 U/mL IL-12 and anti-IL-4) or Th2 polarizing conditions (100 U/mL IL-4, anti-IFN- $\gamma$ ) for 4–6 d.

**Quantitative Real-Time PCR.** Total RNA was isolated using TRIzol reagent and then reverse transcribed using random hexamer primers. Quantitative PCR was then assessed using SYBR Green 1 by iCycler iQ (BioRad) using gene specific primers purchased from Qiagen.

1. Srivastava S, et al. (2009) The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K<sup>+</sup> channel KCa3.1 and CD4 T-cells. *Mol Biol Cell* 20:3783–3791.
2. Borden KL (1998) RING fingers and B-boxes: Zinc-binding protein-protein interaction domains. *Biochem Cell Biol* 76:351–358.
3. Campanero MR, Flemington EK (1997) Regulation of E2F through ubiquitin-proteasome-dependent degradation: Stabilization by the pRB tumor suppressor protein. *Proc Natl Acad Sci USA* 94:2221–2226.
4. Furukawa M, Andrews PS, Xiong Y (2005) Assays for RING family ubiquitin ligases. *Methods Mol Biol* 301:37–46.
5. Bloom J, Pagano M (2005) Experimental tests to definitively determine ubiquitylation of a substrate. *Methods Enzymol* 399:249–266.
6. Wulff H, et al. (2003) The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. *J Clin Invest* 111:1703–1713.
7. Srivastava S, et al. (2006) Phosphatidylinositol-3 phosphatase myotubularin-related protein 6 negatively regulates CD4 T cells. *Mol Cell Biol* 26:5595–5602.
8. Srivastava S, et al. (2005) The phosphatidylinositol 3-phosphate phosphatase myotubularin-related protein 6 (MTMR6) is a negative regulator of the Ca<sup>2+</sup>-activated K<sup>+</sup> channel KCa3.1. *Mol Cell Biol* 25:3630–3638.
9. Sundrud MS, et al. (2003) Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. *J Immunol* 171:3542–3549.
10. Srivastava S, et al. (2006) Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1. *Mol Biol Cell* 17:146–154.
11. Izcue A, et al. (2008) Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. *Immunity* 28:559–570.




**Fig. S1.** TRIM27 partially colocalizes with the transferrin receptor. COS cells expressing GFP-TRIM27 were incubated with rhodamine-transferrin (trf), lysotracker, and mitotracker (Molecular Probes), and colocalization was assessed by fluorescence. Magnification, 60 $\times$ .




**Fig. S2.** TRIM27 negatively regulates KCa3.1 channel activity in Jurkat T cells overexpressing KCa3.1 (Jurkat-KCa3.1) and human CD4 T cells. siRNA knockdown of TRIM27 in Jurkat-KCa3.1 cells was assessed by (A*i*) Western blot and (A*ii*) real-time PCR. The Western blot in A*i* was reprobed with  $\beta$ -actin to demonstrate equal loading between lanes, and the results in A*ii* show the relative amount of TRIM27 expression standardized to a GAPDH control ( $n = 4$ ). Whole-cell patch clamp of (B) control or (C) TRIM27 siRNA-transfected cells. (D) Bar graph summary of TRAM34 inhibited currents plotted at +60 mV from Jurkat-KCa3.1 cells transfected with ctrl or TRIM27 siRNA shown in B and C. Shown are the average from 10 cells per condition. \* $P < 0.001$ . TRIM27 siRNA knockdown cells rescued with either FLAG-TRIM27(WT) and FLAG-TRIM27(RING MT). (E) Purified human CD4 cells were transfected with an siRNA to TRIM27 and then stimulated with anti-CD3 and CD28 antibodies for 48 h. Shown are the bar graph summary of TRAM34 (KCa3.1) and Shk (Kv1.3) inhibited currents plotted at +60 mV. (F) PI3P (100 nM) was added into the pipette solution during patch clamping in Jurkat-KCa3.1 cells overexpressing GFP-TRIM27. Plotted are means  $\pm$  SE from at least three independent experiments. Also shown in F is the failure of PI4P, PI(4,5)P<sub>2</sub>, or PI(3,4,5)P<sub>3</sub> to rescue. \* $P < 0.05$ .





**Fig. S5.** T- and B-cell development is normal in *TRIM27*<sup>-/-</sup> mice. Cells were isolated from spleen, thymus, and lymph node (LN) from WT and *TRIM27*<sup>-/-</sup> mice and stained with antibodies to (A) CD3 and CD19, (B) CD4 and FoxP3, or (C) CD4 and CD8 followed by FACS analysis. All experiments shown are representative of at least four experiments performed on cells isolated from at least four pairs of independent mice.



**Fig. S6.** Activation of T-cell receptor (TCR) stimulation of proximal signaling pathways is similar between *TRIM27*<sup>-/-</sup> and WT Th0 cells. *TRIM27*<sup>-/-</sup> and WT Th0 cells were stimulated with anti-CD3/CD28 antibodies for various times and Western blotted with antibodies to phosphotyrosine (pY), phospho-AKT (pAkt), or phospho-ERK (pERK1/2).

